Myo-Inositol

Myo-inositol is a sugar alcohol your body makes from glucose. It is also present in small amounts in foods like fruit, beans and grains. Inside cells it acts as a second messenger. When insulin or follicle-stimulating hormone arrives at the cell surface, inositol-based molecules carry the signal inwards.^[1]

That dual role on the insulin pathway and the FSH pathway is why myo-inositol has been studied in women with polycystic ovary syndrome. PCOS sits at the intersection of insulin resistance and disordered ovulation. A molecule that touches both makes biological sense as a research target.^[2]

Forms of inositol

Inositol exists in nine isomers. Two matter for women's health. Myo-inositol is the most abundant form in the body and the dominant form in ovarian follicular fluid. D-chiro-inositol is made from myo-inositol by an insulin-driven enzyme. The two work in different tissues at different ratios. The plasma ratio of myo to D-chiro-inositol is roughly 40 to 1. In the ovary that ratio is even higher. Many supplements use a 40:1 myo to D-chiro blend to mirror plasma physiology.^[2]

Most clinical trials in women with PCOS have used myo-inositol on its own or the 40:1 combination. Myo-inositol alone is the most-studied single form for ovulation, cycle regularity and metabolic markers.^[3] nōuxx Cycle Routine uses myo-inositol on its own.

How much you need

Inositol is not a vitamin. Your body makes around 2 to 4 grams of it per day from glucose. A typical mixed diet supplies roughly another gram. There is no recommended daily intake from food agencies.^[1]

Doses used in published clinical research range from 600 mg to 4,000 mg per day. The most common protocol in PCOS trials is 2,000 mg twice daily for a total of 4,000 mg, often combined with 400 micrograms of folic acid.^[3] A 2,000 mg daily dose is the most-studied minimum effective amount and the one with the broadest evidence base for cycle and metabolic outcomes. It is the dose used in nōuxx Cycle Routine. Women looking for the higher therapeutic dose can take a second serving on top.

Significant changes in hormonal markers like SHBG, total testosterone and the LH to FSH ratio require at least 24 weeks of consistent daily use in the published trials. Inositol is a slow-acting input. It is not a same-cycle fix.^[3]

The science on women's health

PCOS and hormonal regulation

The strongest body of research on myo-inositol in women is in PCOS. A 2024 systematic review and meta-analysis informing the international evidence-based PCOS guidelines pooled thirty trials in 2,230 women. Inositol showed benefit on several metabolic measures. The reviewers also flagged that the evidence base is heterogeneous and that confidence in any single outcome remains limited.^[2]

A separate 2023 meta-analysis of twenty-six randomised controlled trials in 1,691 women with PCOS reported that inositol significantly raised the chance of a regular menstrual cycle compared to placebo. Body mass index fell. Free and total testosterone fell. Sex-hormone-binding globulin rose. Fasting glucose and insulin both improved. Inositol was non-inferior to metformin on most outcomes with fewer gastrointestinal side effects.^[3]

Fertility and assisted reproduction

A 2025 systematic review and meta-analysis of eleven trials in 981 women undergoing IVF found that myo-inositol supplementation raised the rate of mature oocytes retrieved and the fertilisation rate. The effect was clearest in women with PCOS.^[4]

Beyond PCOS, the evidence in eumenorrheic women is thin. Most trials have been done in women with a diagnosis of PCOS or in women preparing for fertility treatment. The 2023 Cochrane review of antenatal myo-inositol supplementation in 1,319 pregnant women suggested a reduction in gestational diabetes incidence, with the authors noting low certainty and the need for larger trials.^[5] For women with regular cycles and no metabolic concerns, myo-inositol is best understood as a maintenance input rather than a treatment.

EU authorised health claims

Under EU law, no specific health claim is currently authorised for myo-inositol. The European Food Safety Authority has not approved a claim because the available evidence has not yet met the EU bar for cause-and-effect in healthy adults.

Research suggests myo-inositol may support cycle regularity, hormonal balance and insulin sensitivity in women with PCOS.^[2][3] Most of the published evidence is in PCOS populations. Trials in women without PCOS are limited. Until larger studies in eumenorrheic women confirm an effect at supplemental doses, we do not make formal health claims for myo-inositol.

References

[1] Linus Pauling Institute, Oregon State University. Inositol. Micronutrient Information Center. lpi.oregonstate.edu/mic/other-nutrients/inositol

[2] Fitz V, Graca S, Mahalingaiah S, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. Journal of Clinical Endocrinology & Metabolism 2024;109(6):1630-1655. doi.org/10.1210/clinem/dgad762

[3] Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology 2023;21(1):10. doi.org/10.1186/s12958-023-01055-z

[4] Zhang J, Zhang H, Zhou W, Jiang M, Lin X. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Frontiers in Endocrinology 2025;16:1520362. doi.org/10.3389/fendo.2025.1520362

[5] Motuhifonua SK, Lin L, Alsweiler J, Crawford TJ, Crowther CA. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database of Systematic Reviews 2023;2(2):CD011507. doi.org/10.1002/14651858.CD011507.pub3